long intergenic non-protein coding RNA 1164Genealiases: []
Q-omics provides the consensus-scored LINC01164 profile across patient tissues and cancer cell-line models. LINC01164 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, LINC01164 is differentially expressed in 3, with the highest sampling consensus in READ. Additionally, LINC01164 RNA expression shows 7,751 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUSC, READ, and GBM as cancer lineages where LINC01164 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01164 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01164 survival associations across molecular data types. LINC01164 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01164 RNA expression–survival associations across cancer types. High LINC01164 expression shows unfavorable associations in LUSC, CESC, ESCA, KIRP and COAD, but favorable associations in UVM. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for LINC01164 RNA expression.
This table summarizes LINC01164 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01164. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01164 shows higher tumor expression in READ, LIHC and LUSC. The READ box plot shows higher LINC01164 RNA expression in tumor versus normal tissue (log2 FC = +0.035, t-test p = .038).
This table shows molecular features associated with LINC01164 in patient tissues and cancer cell lines. In patient samples, LINC01164 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
